D-0955-2020 Class II Terminated
FDA drug recall D-0955-2020 was initiated by Fusion IV Pharmaceuticals, Inc. Dba Axia Pharmaceutical on Jan 15, 2020 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Dec 7, 2023).
Recall details
- Product Type
- Drugs
- Report Date
- Mar 11, 2020
- Initiation Date
- Jan 15, 2020
- Termination Date
- Dec 7, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
Glycine Injection,GLYCINE USP 50MG/ML INJECTABLE, For IV, IM Use,30 mL Multi-dose Vial, Rx only, Axia Pharmaceutical 1990 Westwood Blvd. Ste 135, Los Angeles, CA 90025; NDC 71283-0344-3
Reason for recall
Lack of Assurance of Sterility
Distribution pattern
U.S.A. Nationwide and Puerto Rico, Barbados and Dominican Republic
Code information
Lot #: 07012019+52572, Exp 4/6/2020; 10102019+53106, Exp 6/30/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0955-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026